ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2219

Time-Dependent Evaluation of Glucocorticoid Exposure Duration and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis
Abstract Number: 0957

Timeliness of Fetal Echocardiography for Congenital Heart Block Detection in Anti-Ro/La-Positive Pregnancies
Abstract Number: 0778

TNF Inhibitors Display a Modulatory Effect on Serological and Cellular Vaccine Response in Patients with Chronic Inflamatory Diseases
Abstract Number: 1622

TNF Receptor 1 Drives Murine Pulmonary Arterial Hypertension and Is Characterized by Loss of Capillary Endothelial Cells and Pericytes, Smooth Muscle Cell Proliferation, and Alterations in Fibroblast Phenotype
Abstract Number: 0597

TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 1841

To Combine or Not to Combine: Influence of Immunosuppressive Drug Combination in the Induction of Therapeutic Response in Non-infectious Uveitis
Abstract Number: PP03

To Err Is Human: The Need for Patients with Rheumatic and Musculoskeletal Diseases to Continuously Monitor Their Health Care Records
Abstract Number: 0465

Tocilizumab in Large-Vessel Giant Cell Arteritis and Takayasu Arteritis: Multicentric Observational Comparative Study
Abstract Number: 1041

Tofacitinib in Refractory Uveitis – an Observational Study
Abstract Number: 0291

Tofacitinib Leads to Significant Weight Gain – A Real Life Experience of 429 Patients
Abstract Number: 0583

Toll-Like Receptor Ligands Stimulated Monocyte-Derived Langerhans Cell-Like Dendritic Cells Induce Psoriasis-Related Molecules, IL-23 and Delta-Like-4
Abstract Number: 0634

Total Interstitial Inflammation Predicts Chronic Kidney Disease Progression in Patients with Lupus Nephritis
Abstract Number: 1549

Toward Safer Glucocorticoid Therapy
Abstract Number: 2054

Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process
Abstract Number: 1241

Towards a Simplified Fluid-sensitive MRI Protocol in Small Joints of the Hand in Early Arthritis Patients: Reliability Between mDixon and Regular FSE Fat Saturation MRI-sequences

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].